Triple
T17871625
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Amvuttra |
E446848
|
entity |
| Predicate | isProprietaryNameOf |
P24597
|
FINISHED |
| Object | vutrisiran |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: vutrisiran | Statement: [Amvuttra, isProprietaryNameOf, vutrisiran]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: vutrisiran Context triple: [Amvuttra, isProprietaryNameOf, vutrisiran]
-
A.
AMVUTTRA (vutrisiran)
chosen
AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
D.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
E.
GIVLAARI (givosiran)
GIVLAARI (givosiran) is an RNA interference (RNAi) therapeutic used to reduce the frequency of attacks in adults with acute hepatic porphyria.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: isProprietaryNameOf Context triple: [Amvuttra, isProprietaryNameOf, vutrisiran]
-
A.
isTradeNameOf
chosen
Indicates that one name is a commercial or brand designation used for a product, substance, or entity that may also have a different generic or formal name.
-
B.
hasTradeName
Indicates that a product, substance, or entity is known or marketed under a specific commercial or brand name.
-
C.
hasProprietaryStatus
Indicates that something is owned, controlled, or protected as proprietary rather than being public or freely available.
-
D.
isTraditionalProductOf
Indicates that something is a customary or historically established product originating from a particular place, culture, or group.
-
E.
wasProprietaryUntil
Indicates that something was owned or controlled as proprietary (not publicly available or open) up to a specified point in time.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b9f4c22c819093c2680434472894 |
completed | April 10, 2026, 8:51 a.m. |
| NER | Named-entity recognition | batch_69e49aa30ff8819090c51c1d7767e952 |
completed | April 19, 2026, 9:04 a.m. |
| PD | Predicate disambiguation | batch_69e3d8e6d2e88190ad9ef9f8a99f13e6 |
completed | April 18, 2026, 7:17 p.m. |
Created at: April 10, 2026, 10:18 a.m.